Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment.
David C de LeeuwGert J OssenkoppeleJeroen J W M JanssenPublished in: Current oncology reports (2022)
Several factors, like age, performance status, and comorbidities, play a role in fitness and are associated with outcome. Comorbidity scoring systems and geriatric assessments are tools to help physicians select the most appropriate treatment for each patient. The addition of venetoclax, targeted therapy with IDH1/2 and FLT3 inhibitors, and enhanced formulas of existing drugs like CPX-351 and oral azacitidine have improved responses and outcomes. New drugs and combination therapies have increased the therapeutic options for elderly AML patients but determination of fitness and disease biology is essential to select patient-tailored treatments.
Keyphrases
- acute myeloid leukemia
- end stage renal disease
- allogeneic hematopoietic stem cell transplantation
- case report
- physical activity
- primary care
- body composition
- ejection fraction
- chronic kidney disease
- combination therapy
- metabolic syndrome
- skeletal muscle
- tyrosine kinase
- middle aged
- hip fracture
- tandem mass spectrometry
- chronic lymphocytic leukemia